NCT03272256View on ClinicalTrials.gov

Phase 1 Study of IM156 in Patients With Advanced Solid Tumor and Lymphoma

PHASE1CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

October 9, 2017

Primary Completion Date

December 2, 2019

Study Completion Date

July 28, 2020

Conditions
Advanced Solid Tumor
Interventions
DRUG

IM156

Sequential 3+3 design.

Trial Locations (3)

13496

CHA Bundang Medical Center, Seongnam-si

Unknown

Asan Medical Center, Seoul

Yonsei University Severance Hospital, Seoul

Sponsors
All Listed Sponsors
lead

ImmunoMet Therapeutics, Inc.

INDUSTRY